Studies on bi-layer osmotic pump tablets of water-insoluble allopurinol with large dose: In vitro and in vivo

Drug Development and Industrial Pharmacy

Volumn 33, Issue 9, 2007, Pages 1024-1029

  Nie, Shu Fang ^a   Li, Wei ^a   Luan, Lin ^a   Pan, Weisan ^a   Wang, Xun ^b  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Allopurinol; Bi layer osmotic pump tablets; In vitro in vivo correlation; Oxypurinol; Pharmacokinetics

Indexed keywords

ALLOPURINOL; MACROGOL; OXIPURINOL; SODIUM CHLORIDE; SUSPENDING AGENT;

ANIMAL EXPERIMENT; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOG; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; IN VITRO STUDY; IN VIVO STUDY; METABOLITE; NONHUMAN; OSMOSIS; SINGLE DRUG DOSE; SLOW DRUG RELEASE;

ALLOPURINOL; ANIMALS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOGS; EXCIPIENTS; GOUT SUPPRESSANTS; OSMOSIS; OSMOTIC PRESSURE; OXYPURINOL; POLYETHYLENE GLYCOLS; SODIUM CHLORIDE; SOLUBILITY; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 34648818167     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040601179897     Document Type: Article

References (21)

1. Barthel, W., Hüller, G, Haustein, K. O. et al. (1999). Bioequivalence of Allopurinol-containing tablet preparations. Int. J. Clin. Pharmacol. Ther., 37(3), 148-152.
2. Chen, M. L., André, J. J. (1991). The role of metabolites in bioequivalency assessment. I. Linear pharmacokinetics without first-pass effect. Pharm. Res., 8(1), 25-32.
3. Chen, C. M., Lee, D. Y., & Xie, J. (1998). Controlled release formulation for water insoluble drugs in which a passageway is formed in situ [P]. US Patent: 5736159, 1998-04-07.
4. FDA. (1995). Guidance for Industry: SUPAC-IR: Immediate-Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation (I).
5. Goldenberg, M. M. (1999). An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder. Clin Ther., 21(4), 634-642.
6. Gupta, S. K., Shah, J. C., Guinta, D. et al. (1998). Multiple-dose pharmacokinetics and pharmacodynamics of OROS and immediate-release amitriptyline hydrocholoride formulations. J. Clin. Pharmacol., 38(1), 60-67.
7. Hou, H. M., & Zhu, J. P. (1982). The preparation and in vitro release of OROS(indometacin). Chin. J. Hospital Pharm., 2(5), 265-266.
8. Keith, S. (2006). Advances in psychotropic formulations. Prog. Neuro-Psychopharmacol. Biol. Psychiatry., 30(6), 996-1008
9. Kuczynski, A. L., Ayer, A. D., Wong, P. S. L. et al. (1991). Oral hypoglycemic glipizide granulation [P].US:5024843, 1991-06-18.
10. Liu, L., Ku, J., Khang, G. et al. (2000). Nifedipine controlled delivery by sand-wished osmotic tablet system. J. Control. Release., 68(2), 145-156.
11. Modi, N. B., Lindemulder, B., & Gupta, S. K. (2000). Single- and multi-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. J. Clin. Pharmacol., 40(4), 379-388.
12. 7m-β-CD. Pharm. Res., 15(10), 1562-1568.
13. 7m-β-CD as both a solubilizing and osmotic agent. J. Control. Release., 60(2-3), 311-319.
14. 7m-β-cyclodextrin as both a solubilizing and osmotic pump agent. J. Control. Release., 58(1), 29-38.
15. 7m-β-CD. Pharm. Res., 16(4), 549-554.
16. Swanson, D. R., Barclay, B. L., Wong, P. S. L. et al. (1987). Nifedipine gastrointestinal therapeutic system. Am. J. Med., 83, 3.
17. Thombre, A. G., Appel, L. E., Chidlaw, M. B. et al. (2004). Osmotic drug delivery using swellable- core technology. J. Control. Release., 94, 75-89.
18. Verma, R. K., Krishna, D. M., & Garg, S. (2000b). Formulation aspects in the development of osmotically controlled oral drug delivery systems. J. Control. Release., 79, 7-27.
19. Verma, R. K., Mishra, B., & Garg, S. (2000a). Osmotically controlled oral drug delivery. Drug Dev. Ind. Pharm., 26(7): 695-708.
20. Walter-Sack, I., de Vries, J. X., Ernst, B. et al. (1996). Uric acid lowering effect of oxipurinol sodium in hyperuricemic patients. Therapeutic equivalence to allopurinol. J. Rheumatol., 23, 498-501.
21. Walter-Sack, I., de Vries, J. X., Kreiner, C. et al. (1995). Disposition and uric acid lowering effect of oxipurinol: Comparison of different oxipurinol formulations and allopurinol in healthy individuals. Eur. J. Clin. Pharmacol., 49, 215-220.